UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): June 1825, 2026

Cadrenal Therapeutics, Inc.

(Exact name of registrant as specified in charter)

Delaware		001-41596		88-0860746
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

822 A1A North, Suite 306

Ponte Vedra, Florida 32082

(Address of principal executive offices and zip code)

(904) 300-0701

(Registrant’s telephone number including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbols		Name of each exchange on which registered
Common Stock, par value $0.001 per share		CVKD		The Nasdaq Stock Market LLC (Nasdaq Capital Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 75.0102. ~~Regulation~~Departure FDof ~~Disclosure~~Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

OnAppointment ~~June~~of 18, 2026, Cadrenal Therapeutics, Inc. (the “Company”) issued a press release announcing its plans to submit a Rare Pediatric Disease Designation (“RPDD”) request to the U.S. Food and Drug Administration (“FDA”) for tecarfarin as a treatment for pediatric patients with Kawasaki disease who develop coronary artery aneurysms (“CAAs”) and require chronic oral anticoagulation.CFO

~~The~~On ~~Company~~June ~~also~~25, ~~disclosed~~2026, ~~its~~the ~~dual-track~~Board ~~portfolio~~of Directors (the ~~strategy~~“Board”) ~~that~~of ~~includes:~~Cadrenal Therapeutics, Inc. (ithe “Company”) ~~The~~appointed ~~Global~~John ~~Pharma~~P. ~~Track:~~Sharp ~~Focusing~~as onInterim ~~CAD-1005~~Chief Financial Officer of the Company. In connection with the appointment, aQuang ~~first-in-class~~X. ~~12-LOX~~Pham ~~inhibitor;~~ceased ~~and~~to ~~(ii)~~serve ~~The~~as ~~Regional~~the &Company’s Interim Chief Financial Officer. ~~Rare~~Mr. ~~Disease~~Sharp’s ~~Track:~~biography ~~Focusing~~is onbelow. ~~tecarfarin~~The Company is conducting a search for ~~Kawasaki~~a ~~disease~~permanent Chief Financial Officer.

AMr. ~~copy~~Sharp, ofage ~~the~~61, ~~press~~is ~~release~~a isseasoned ~~furnished~~finance ~~herewith~~executive aswith ~~Exhibit~~more ~~99.1.~~than ~~The~~30 ~~information~~years inof ~~this~~experience ~~Item~~in ~~7.01~~financial and inbusiness ~~the~~planning ~~press~~and ~~release~~currently ~~furnished~~serves as ~~Exhibit~~a ~~99.1~~Senior toDirector ~~this~~at ~~Current~~Lohman ~~Report~~& ~~on Form 8-K~~Associates. ~~shall~~He ~~not~~has beserved ~~deemed~~as toChief beFinancial ~~“filed”~~Officer for ~~purposes~~several ofbiopharmaceutical ~~Section~~companies 18since ofApril ~~the~~2007. ~~Securities~~He ~~Exchange~~has ~~Act~~been Chief Financial Officer of ~~1934~~Skye Bioscience, asInc. ~~amended~~since March 31, or2026. ~~otherwise subject~~From December 2022 to ~~the~~October ~~liabilities~~2025, ofhe ~~that~~served ~~section~~as orChief ~~Sections~~Financial 11Officer of SaNOtize Research and ~~12(a)(2)~~Development ofCorp. ~~the~~Prior ~~Securities~~to ~~Act~~this, he served as Chief Financial Officer of ~~1933~~PhaseBio Pharmaceuticals, asInc. ~~amended~~from April 2016 to November 11, 2022; of HUYA Bioscience International, LLC, from March 2014 to December 2015; and ~~shall~~of ~~not~~Nasdaq-listed beLigand ~~incorporated~~Pharmaceuticals from April by2007 ~~reference~~to ~~into~~March ~~any~~2014. ~~filing~~He ~~with~~is ~~the~~also ~~Securities~~a ~~and~~former ~~Exchange~~auditor ~~Commission~~with ~~(the~~PricewaterhouseCoopers ~~“SEC”)~~LLP. ~~made~~Mr. bySharp ~~the~~received ~~Company,~~a ~~whether~~BS ~~made~~in ~~before~~business administration with oran ~~after~~emphasis ~~the~~in ~~date~~accounting ~~hereof,~~from ~~regardless~~San ofDiego ~~any~~State ~~general~~University ~~incorporation~~and ~~language~~is ina ~~such~~certified ~~filing~~public accountant (inactive) in California.

~~Item~~Effective 8June 25, 2026, in connection with the appointment of Mr.01 Sharp, the Company entered into Scope of Work Number Five (“SOW5”), which sets forth the services to be provided by Mr. ~~Other~~Sharp ~~Events~~as the Company’s Interim Chief Financial Officer. The SOW5 is subject to the provisions of a Master Services Agreement, dated August 21, 2024 (the “Master Services Agreement”), between the Company and Lohman & Associates, Inc. (“L&A”), pursuant to which L&A agreed to provide accounting, business strategy and consulting, fractional chief financial officer services, and human resources consulting services to the Company, as more specifically set forth in one or more Statements of Work (“SOWs”) issued under the Master Services Agreement and signed by the Company and L&A, including SOW5. Pursuant to the Master Services Agreement and SOW5, L&A will bill the Company at a flat rate of $455/hour for up to 24 hours per week of Mr. Sharp’s services as the Company’s Interim Chief Financial Officer. Any services above 24 hours in a week, any out-of-scope services, any travel or lodging expenses, any technology or administrative surcharges, and any changes to the hourly rates set forth therein must be approved in writing by the parties.

OnExcept ~~June~~as ~~18,~~set ~~2026~~forth above, ~~the~~there ~~Company~~are ~~issued~~no aarrangements or ~~press~~understandings ~~release announcing~~between ~~its~~Mr. ~~plans~~Sharp toand ~~submit~~any aother ~~RPDD~~person ~~request~~that toresulted ~~the~~in ~~FDA~~Mr. ~~for~~Sharp's ~~tecarfarin~~appointment as aChief ~~treatment~~Financial ~~for~~Officer ~~pediatric~~of ~~patients~~the ~~with~~Company. Mr. ~~Kawasaki~~Sharp ~~disease~~has ~~who~~no family relationships that are required to be disclosed pursuant to Item 401(d) of Regulation S-K. There are no related-party ~~develop~~transactions ~~coronary~~between ~~artery~~the ~~aneurysms~~Company and Mr. Sharp that would require ~~chronic~~disclosure ~~oral~~under ~~anticoagulation~~Item 404 of Regulation S-K.

The ~~Company~~foregoing ~~also~~descriptions ~~disclosed~~of ~~its~~the ~~dual-track~~MSA ~~portfolio~~and the ~~strategy~~Statement ~~that~~of ~~includes:~~Work ~~(i)~~are ~~The~~not ~~Global~~intended ~~Pharma~~to ~~Track:~~be ~~Focusing~~complete onand ~~CAD-1005,~~are asubject ~~first-~~to and qualified in~~-class~~ ~~12-LOX~~their ~~inhibitor;~~entirety ~~and~~by ~~(ii)~~reference ~~The~~to ~~Regional~~the &full text of ~~Rare~~the ~~Disease~~MSA ~~Track:~~and ~~Focusing~~the onStatement ~~tecarfarin~~of ~~for~~Work, ~~Kawasaki~~copies ~~disease~~of which are attached hereto as Exhibits 10.1 and 10.2, respectively, and incorporated herein by reference.

Resignation of Steven Zelenkofske

On June 28, 2026, Steven Zelenkofske, a Class III member of the Board, notified the Company of his resignation from the Board, effective June 30, 2026. Mr. Zelenkofske’s resignation was not the result of any disagreement with the Company regarding any matter relating to the Company’s operations, policies, or practices.

Realignment of Classes of the Board of Directors

In connection with Dr. Zelenkofske’s resignation, the Board approved a process to realign its members so that the Board would be divided into three classes as nearly equal in size as practicable. Accordingly, on June 29, 2026, Dr. Glynn Wilson resigned as a Class I director. The Board appointed him as a Class III director, effective immediately, to serve until the Corporation’s 2028 annual meeting of stockholders, or until his successor is duly elected and qualified, or until his earlier death, resignation, or removal. In addition, the Board reappointed Dr. Wilson to the Audit Committee and the Nominating and Corporate Governance Committee. Dr. Wilson was also appointed to the Compensation Committee. Dr. Wilson will continue to receive the standard compensation available to the Company’s non-employee directors, which, for the fiscal year ending December 31, 2026, is an annual fee of $35,000 for serving on the Board, as well as equity awards from time to time.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

The following exhibits are furnished with this Current Report on Form 8-K:

Exhibit Number		Exhibit Description
99.1		Press Release, issued by Cadrenal Therapeutics, Inc. on June 18, 2026
10.1		Master Services Agreement, dated August 21, 2024, between the Company and Lohman & Associates, Inc.
10.2		Statement of Work Number Five, effective as of June 25, 2026, pursuant to Master Services Agreement
104		Cover Page Interactive Data File (the cover page XBRL tags are embedded within in the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: June 18, 2026	CADRENAL THERAPEUTICS, INC.
Dated: June 29, 2026	CADRENAL THERAPEUTICS, INC.
	By:	/s/ Quang X. Pham
	Name:	Quang X. Pham
	Title:	Chairman and Chief Executive Officer

Filing Compare · Cadrenal Therapeutics, Inc.